Clinical Trial Update: Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating TI-0093 injections for HPV-16 positive recurrent or metastatic cancers is currently recruiting. The target indications inclu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• TI-0093

Snippet

Sponsor: Therorna | Conditions: HPV 16+ Recurrent or Metastatic Cancer, HNSCC | Phase 1 | Status: RECRUITING